Skip to main content
. 2019 Oct 16;9(25):7906–7923. doi: 10.7150/thno.38425

Figure 7.

Figure 7

Expected challenges and perspectives for the repurposing of current nanoparticle-based drug delivery systems for cancer immunotherapy. (A) Repurposing strategies to overcome cancer heterogeneity and complexity for improved drug delivery efficiency. (B) Repurposing strategies improved tumor specificity of immunotherapeutics by activating immune responses with fewer side effects. (C) Repurposing strategies for precise and large-scale commercial production of immunotherapeutics.